Evidence map›Paper›PMID 39747754›Full record

ArticleInsights into imaging2025

Diagnostic value of dual-layer spectral detector CT parameters for differentiating high- from low-grade bladder cancer.

Li Chen, Lili Xu, Xiaoxiao Zhang, Jiahui Zhang, Xin Bai, Qianyu Peng, Erjia Guo, Xiaomei Lu, Shenghui Yu, Zhengyu Jin and 4 more

Abstract read
In one paragraph

Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Li ChenDepartment of Radiology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Lili XuDepartment of Radiology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, People's Republic of China.
Xiaoxiao ZhangDepartment of Radiology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Jiahui ZhangDepartment of Radiology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Xin BaiDepartment of Radiology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Qianyu PengDepartment of Radiology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Erjia GuoDepartment of Radiology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Xiaomei LuCT Clinical Science, Philips Healthcare, Shenyang, People's Republic of China.
Shenghui YuCT Clinical Science, Philips Healthcare, Beijing, People's Republic of China.
Zhengyu JinDepartment of Radiology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Gumuyang ZhangDepartment of Radiology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. zhang_stacey@163.com.
Yi XieDepartment of Urology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. xieyi@pumch.cn.
Huadan XueDepartment of Radiology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. bjdanna95@163.com.
Hao SunDepartment of Radiology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. sunhao_robert@126.com.ORCID http://orcid.org/0000-0002-9606-9066

Funding

National High-Level Hospital Clinical Research Funding 2022-PUMCH-A-033National High-Level Hospital Clinical Research Funding 2022-PUMCH-A-035National High-Level Hospital Clinical Research Funding 2022-PUMCH-B-069the Beijing natural Science Foundation L232133the CAMS Innovation Fund for Medical Sciences 2022-12M-C&T-B-019the Natural Science Foundation of China No.81901742
6 · The paper itself

Abstract

objectivesThis study aimed to investigate the diagnostic value of spectral parameters of dual-layer spectral detector computed tomography (DLCT) in distinguishing between low- and high-grade bladder cancer (BCa).

methodsThis single-center retrospective study included pathologically confirmed BCa patients who underwent preoperative contrast-enhanced DLCT. Patients were divided into low- and high-grade groups based on pathology. We measured and calculated the following spectral CT parameters: iodine density (ID), normalized ID (NID), arterial enhancement fraction (AEF), extracellular volume (ECV) fraction, virtual non-contrast (VNC), slope of the attenuation curve, and Z effective (Z

resultsThe study included 64 patients (mean age, 64 ± 11.0 years; 46 men), of whom 42 had high-grade BCa and 22 had low-grade BCa. Univariate analysis revealed that differences in ID and NID in the corticomedullary phase, AEF, ECV, VNC, and Z

conclusionUsing DLCT AEF could help distinguish high-grade from low-grade BCa. CRITICAL RELEVANCE STATEMENT: This research demonstrates that the arterial enhancement fraction (AEF), a parameter derived from dual-layer spectral detector CT (DLCT), effectively distinguishes between high- and low-grade bladder cancer, thereby aiding in the selection of appropriate clinical treatment strategies. KEY POINTS: This study investigated the value of dual-layer spectral detector CT in the assessment of bladder cancer (BCa) histological grade. The spectral parameter arterial enhancement fraction could help determine BCa grade. Our results can help clinicians formulate initial treatment strategies and improve prognostications.

Indexed as

Arterial enhancement fractionComputed tomography urographyPathologySpectral CTUrinary bladder neoplasms

Identifiers

PMID39747754
PMCPMC11695557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.